C.R. Bard Reaffirmed Neutral - Analyst Blog

A generic image of a person with a pen and calculator
Credit: Shutterstock photo

We retain our Neutral recommendation for C.R. Bard ( BCR ) following its mixed third quarter 2011 results. Earnings for the quarter topped the Zacks Consensus Estimate while sales missed the forecast.

Revenue rose 6% year over year, fueled by healthy contributions from the company's Vascular and Oncology businesses, backed by SenoRx acquisition and overseas operations.

C.R. Bard's well-diversified end-markets and vast product portfolio insulate it from fluctuations in any single therapeutic category. The company's resource depth and focused innovation are its major competitive advantages. C.R. Bard's incremental R&D investment should boost its pipeline and give way to product innovation/differentiation.

C.R. Bard is also making prudent use of cash in the form of acquisitions and share repurchases. During its third quarter call, the company announced its acquisition of Colorado-based Medivance Inc for roughly $250 million. The acquisition augurs well with C.R. Bard's business model and will boost its offerings in the critical care settings (including myocardial infarction, traumatic brain injury and stroke).

We expect new products to drive organic revenue growth and help C.R. Bard to meet its sales objective. The new Ventralex ST umbilical hernia repair product, Ventrio ST ventral hernia repair system and the Echo PS mesh positioning system should support growth going ah ead.

However, heightened competition and pricing/procedure volume pressure remain areas of concern. C.R. Bard faces a mix of competitors ranging from large manufacturers with multiple business lines like Boston Scientific ( BSX ) and Johnson & Johnson ( JNJ ) to smaller manufacturers that offer a limited selection of products like Angiodynamics ( ANGO ).

Moreover, a soft U.S. market may continue to weigh on the company's results. Our recommendation on the stock is in tandem with a short-term Zacks #3 Rank (Hold).

ANGIODYNAMICS ( ANGO ): Free Stock Analysis Report

BARD C R INC ( BCR ): Free Stock Analysis Report

BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report

JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More